Skip to content
Open access

Low blood pressure and the effect of SGLT2 inhibitors in heart failure with reduced ejection fraction: data from the China Cardiovascular Association Database-Heart Failure Center Registry

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

In this nation-wide real-world study, SGLT2i therapy was associated with substantial reductions in mortality across the range of SBP, including those lower than 100mmHg.

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become a cornerstone of treatment in heart failure with reduced ejection fraction (HFrEF) management, but data on their use in HFrEF with systolic blood pressure (SBP) lower than 100 mmHg remain limited. To assess the real-world efficacy of SGLT2i in HFrEF patients with low SBP. Data were from the China Cardiovascular Association Database-Heart Failure Center Registry between January 1, 2017 to December 31, 2022, which were linked to the National Mortality Registration Information Management System by the Chinese Centre for Disease Control and Prevention. Eligible patients were HFrEF aged 18 years or older with blood pressure, glycated hemoglobin and medication records, and without symptomatic hypotension. The primary outcome was all-cause mortality. A 1:1 propensity score-matched (PSM) analyses and inverse probability of treatment weighting (IPTW) were used to adjust baseline characteristics. After PSM, 7,476 pairs of patients were included in the SGLT2i and non-SGLT2i groups, of whom median age was 66, 4,744 (31.7%) were female. A total of 2,985 patients had a baseline SBP ≤100 mmHg; 6,871 >100 but ≤120 mmHg; and 5096 >120 mmHg. In non-SGLT2i group, the risk of all-cause death was 12.8 events per 100 patient-years at >120 mmHg, 14.0 at 100-120 mmHg, and 19.2 at ≤100 mmHg. The benefit of SGLT2i on mortality was consistent in patients with low SBP: the HR for SGLT2i vs non-SGLT2i was 0.79 (95% CI: 0.66-0.94) for SBP >120 mmHg, 0.77 (95% CI: 0.66-0.89) for 100<SBP ≤120 mmHg, and 0.77 (95% CI: 0.63-0.93) for SBP ≤100 mmHg. No significant interaction was observed between benefit of SGLT2i use and baseline systolic blood pressure (pinteraction = 0.94). Patients presenting with low SBP experienced an increase in SBP at 1, 3, and 12 months follow-up, regardless treatment group. In the baseline SBP ≤100 mmHg group, a modest between-group reduction in SBP, adjust against the non-SGLT2i control, was observed at 1 month (pinteraction = 0.002) and 3 months (pinteraction = 0.009), but no longer significant at 12 months (pinteraction = 0.456). These outcomes were similar in IPTW analysis including 8,661 patients treated with SGLT2i and 24,876 patients without SGLT2i. In this nation-wide real-world study, SGLT2i therapy was associated with substantial reductions in mortality across the range of SBP, including those lower than 100mmHg.SGLT2i reduces mortality across all SBP groupChanges of SBP during follow-up

Read PDF

Similar papers

Open access Oct 2026

Survival benefits of SGLT2 inhibitors in very elderly patients with heart failure with preserved ejection fraction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a foundational therapy for heart failure with preserved ejection fraction (HFpEF). However, pivotal randomized clinical trials have predominantly underrepresented the elderly population, leaving the real-world efficacy of SGLT2i in this specific d...

Y. Ge, H. Wang, J.-F. Yang · 0 citations
Nov 2026

Abstract 15216: Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction and Active Malignancy: A Propensity Matched Retrospective Analysis

Background: Patients living with both heart failure with reduced ejection fraction (HFrEF) and active malignancy represent one of the most challenging populations in modern cardiology. Despite carrying the highest combined cardiovascular and oncologic risk, they have been excluded from every landmark sodium glucose...

Satesh Kumar, Fnu Sugandh, Mahima Khatri et al. · 0 citations
Open access Oct 2026

Efficacy of sacubitril/valsartan on mortality in asymptomatic hypotensive HFrEF: data from the China Cardiovascular Association Database-Heart Failure Center Registry

Despite guidelines recommending rapid initiation and up-titration of Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), concerns of asymptomatic low blood pressure (BP) often limit optimization of GDMT. Hypotension is associated with worse outcomes but how this ass...

Z. Qiu, Z. Li, Y. Chen et al. · 0 citations
Nov 2026

Abstract 8050: Sodium-Glucose Cotransporter-2 Inhibitors Increase Estimated Glomerular Filtration Rate Slope and Ameliorate Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients with Heart Failure

Background: Treatment of sodium-glucose cotransporter 2 inhibitors (SGLT2is) has been demonstrated to decrease cardiovascular events in patients with heart failure (HF) regardless of ejection fraction. Moreover, SGLT2i treatment also prevented deterioration of renal function in those with chronic kidney disease (CKD...

M. Harada, Y. Motoike, A. Nishimura et al. · 0 citations
Open access Oct 2026

Early Initiation of SGLT2 inhibitor and Mortality in Heart Failure With Reduced Ejection Fraction: A Target Trial Emulation Study.

BACKGROUND AND AIMS Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), yet the optimal timing of initiation in routine clinical practice remains uncertain. We investigated the impact of early initiation of SGLT2i within 30 days of H...

G. Mkoma, A. Hviid, B. Pasternak et al. · 0 citations
Review Open access Oct 2026

SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in type 2 diabetes mellitus.

Ahmed Elbataa, A. Mansour, Ahmed Elazab et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.